Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
— Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study — — RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2 and Phase 3 Studies in Pregnant Women — — RLYB212 Phase 2 Study Expected To Commence in 2H 2024 — NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) … [Read more…]